Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo.

Asthma exacerbations in people treated with mepolizumab result in less peak expiratory flow reduction than placebo but similar symptom scores. Symptoms recover slower, indicating these exacerbations may be less prednisolone responsive. https://bit.ly/3xQsFRB.
Competing Interests: Conflict of interest: D.J. Bratton and S.W. Yancey are employees of GSK and hold stock/stock options in GSK. S.W. Yancey has since retired. I. Howell, G. Hynes and R. Shrimanker have no relevant competing interests to disclose. I.D. Pavord reports personal fees from AstraZeneca, GSK, Boehringer Ingelheim, Sanofi/Regeneron, Circassia, Merck, Novartis, Mundipharma, Teva and Knopp; and grants and personal fees from Chiesi and Afferent. L.G. Heaney reports personal fees or sponsorship from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Roche/Genentech, Sanofi, Amgen, Aerocrine and Napp; and grants from AstraZeneca, Boehringer Ingelheim, GSK and Napp.
(Copyright ©The authors 2024.)